Clinical Trial: AT1001 for the Treatment of Long COVID
Study Status: Completed
Recruit Status: RECRUITING
Condition: Long COVID
Study Type: INTERVENTIONAL
Official Title: Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Larazotide (AT1001) for the Treatment of Long COVID in Children and Young Adults
Brief Summary:
The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and young adults 7 to ?21 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia.AT1001 (n=32) or placebo (n=16) will be administered orally four times a day (QID) for 21 days.
Read more